Molecular Data Inc.
Molecular Data Inc. Fundamental Analysis
Molecular Data Inc. (MKD) shows weak financial fundamentals with a PE ratio of -1.08, profit margin of -4.32%, and ROE of 2.68%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 80.3/100 based on profitability, valuation, growth, and balance sheet metrics. The B+ grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze MKD's fundamental strength across five key dimensions:
Efficiency Score
WeakMKD struggles to generate sufficient returns from assets.
Valuation Score
ExcellentMKD trades at attractive valuation levels.
Growth Score
WeakMKD faces weak or negative growth trends.
Financial Health Score
ModerateMKD shows balanced financial health with some risks.
Profitability Score
WeakMKD struggles to sustain strong margins.
Key Financial Metrics
Is MKD Expensive or Cheap?
P/E Ratio
MKD trades at -1.08 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, MKD's PEG of -0.00 indicates potential undervaluation.
Price to Book
The market values Molecular Data Inc. at -12.71 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 0.32 times EBITDA. This is generally considered low.
How Well Does MKD Make Money?
Net Profit Margin
For every $100 in sales, Molecular Data Inc. keeps $-4.32 as profit after all expenses.
Operating Margin
Core operations generate -4.36 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $2.68 in profit for every $100 of shareholder equity.
ROA
Molecular Data Inc. generates $-47.90 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
FCF Per Share
Each share generates $-1.87 in free cash annually.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-1.08
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.00
vs 25 benchmark
P/B Ratio
Price to book value ratio
-12.71
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.00
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
-2.55
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.96
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
2.68
vs 25 benchmark
ROA
Return on assets percentage
-0.48
vs 25 benchmark
ROCE
Return on capital employed
42.59
vs 25 benchmark
How MKD Stacks Against Its Sector Peers
| Metric | MKD Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -1.08 | 27.01 | Better (Cheaper) |
| ROE | 268.42% | 949.00% | Weak |
| Net Margin | -4.32% | -16159.00% (disorted) | Weak |
| Debt/Equity | -2.55 | 0.48 | Strong (Low Leverage) |
| Current Ratio | 0.96 | 4.42 | Weak Liquidity |
| ROA | -47.90% | -6411.00% (disorted) | Weak |
MKD outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Molecular Data Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Cyclical, Commodity, Value
EPS CAGR
N/A
Industry Style: Cyclical, Commodity, Value
FCF CAGR
N/A
Industry Style: Cyclical, Commodity, Value